Synartro Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.08M

  • Investors
  • 3

Synartro General Information

Description

Developer of local injection treatments designed to provide sustained efficacy for osteoarthritis. The company develops local injection treatments that provide superior and sustained efficacy without systemic side effects, which leads to improved treatments using patented delivery technology that offers a sustained drug release combined with existing proven drugs, enabling clinicians to slow down and stop the disease progression entirely.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Vasagatan 28
  • 111 20 Stockholm
  • Sweden
+46 076-027
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • Vasagatan 28
  • 111 20 Stockholm
  • Sweden
+46 076-027

Synartro Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synartro Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 09-Oct-2025 $2.08M Completed Pre-Clinical Trials
4. Later Stage VC 01-May-2023 Completed Pre-Clinical Trials
3. Seed Round 25-Oct-2021 Completed Pre-Clinical Trials
2. Seed Round 04-Nov-2020 $1.92M $7.92M Completed Pre-Clinical Trials
1. Seed Round 05-May-2020 $6M $6M Completed Pre-Clinical Trials
To view Synartro’s complete valuation and funding history, request access »

Synartro Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
To view Synartro’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Synartro Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of local injection treatments designed to provide sustained efficacy for osteoarthritis. The company develops
Drug Discovery
Stockholm, Sweden
6 As of 2026

Basel, Switzerland
 

Saint-Prex, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synartro Competitors (6)

One of Synartro’s 6 competitors is Novartis, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland
Ferring Private Equity-Backed Saint-Prex, Switzerland
Sanofi Corporation Gentilly, France
GSK Corporation London, United Kingdom
Anika Therapeutics Formerly VC-backed Bedford, MA
To view Synartro’s complete competitors history, request access »

Synartro Patents

Synartro Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202216467-D0 Pharmaceutical formulation Inactive 04-Nov-2022
JP-2026528114-A Liquid formulation Pending 16-Aug-2022
EP-4777151-A1 Liquid formulations Pending 16-Aug-2022
WO-2024038088-A1 Liquid formulations Inactive 16-Aug-2022
JP-2026526254-A Method for preparing a sterilization composition Pending 16-Aug-2022 A61K47/61
To view Synartro’s complete patent history, request access »

Synartro Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synartro Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Phase2Phase Biopharma Venture Capital Minority
Sciety Venture Capital Minority
Linc (Sweden) Venture Capital Minority
To view Synartro’s complete investors history, request access »

Synartro FAQs

  • When was Synartro founded?

    Synartro was founded in 2011.

  • Where is Synartro headquartered?

    Synartro is headquartered in Stockholm, Sweden.

  • What is the size of Synartro?

    Synartro has 6 total employees.

  • What industry is Synartro in?

    Synartro’s primary industry is Drug Discovery.

  • Is Synartro a private or public company?

    Synartro is a Private company.

  • What is Synartro’s current revenue?

    The current revenue for Synartro is .

  • How much funding has Synartro raised over time?

    Synartro has raised $14.7M.

  • Who are Synartro’s investors?

    Phase2Phase Biopharma, Sciety, and Linc (Sweden) have invested in Synartro.

  • Who are Synartro’s competitors?

    Novartis, Ferring, Sanofi, GSK, and Anika Therapeutics are some of the 6 competitors of Synartro.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process